Abstract: The present invention provides a fusion protein, which includes: (a) a tissue plasminogen activator or a variant thereof; (b) a disintegrin or a variant thereof; and (c) a linker positioned between the tissue plasminogen activator or the variant thereof and the disintegrin or the variant thereof and the linker having an amino acid sequence selected from SEQ ID Nos.: 1-7. The present invention also provides a method for treating or preventing a disease related to thrombosis by using the foregoing fusion protein.

Abstract: Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.

Abstract: Disintegrin variants that bind specifically to one or more of ?5?1 and ?v integrins, such as ?v?1, ?v?3, ?v?5, ?v?6 and ?v?8, but with reduced binding activity to ?IIb?3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an ?v integrin or an ?5?1 integrin.

Abstract: Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.

Abstract: Disintegrin variants that bind specifically to one or more of ?5?1 and ?v integrins, such as ?v=1, ?v?3, ?v?5, ?v?6 and ?v?8, but with reduced binding activity to ?IIb?3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an ?v integrin or an ?5?1 integrin.

Abstract: Disintegrin variants that bind specifically to one or more of ?5?1 and ?v integrins, such as ?v?1, ?v?3, ?v?5, ?v?6 and ?v?8, but with reduced binding activity to ?IIb?3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an ?v integrin or an ?5?1 integrin.

Abstract: The present invention provides isolated polypeptides comprising a modified fibronectin fragment that comprises FNIII 10 and optionally further comprising FNIII 9. Also provided are pharmaceutical compositions comprising the polypeptides and methods of making and using the polypeptides.

Abstract: Disintegrin variants that bind specifically to one or more of ?5?1 and ?v integrins, such as ?v?1, ?v?3, ?v7?5, ?v?6 and ?v?8, but with reduced binding activity to ?IIb?3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an ?v integrin or an ?5?1 integrin.

Abstract: The present invention provides isolated polypeptides comprising a modified fibronectin fragment that comprises FNIII 10 and optionally further comprising FNIII 9. Also provided are pharmaceutical compositions comprising the polypeptides and methods of making and using the polypeptides.

Abstract: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.

Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.

Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.

Abstract: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.

Abstract: Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin ?v?3 receptor-antagonist activity and substantially reduced integrin ?llb?3 and/or ?5?1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin ?llb?3 and/or ?5?1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of ?v?3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis.

Abstract: The invention generally relates to fusion proteins comprising a rhodostomin variant having an RGD motif variant 48ARLDDL53, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA). The invention also relates to the use of these fusion proteins for treatment and prevention of ?v?3 integrin-associated diseases.

Abstract: Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin ?v?3 receptor-antagonist activity and substantially reduced integrin ?llb?3 and/or ?5?1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin ?llb?3 and/or ?5?1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of ?v?3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis.